Fused heterocycles as inhibitors of VEGF receptor and HGF receptor signaling
US8093264B2 · kind B2 · utility
2Cited by
16References
25Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 19, 2006 |
| Grant date | Jan 10, 2012 |
| Priority date | — |
| Expiry date | Nov 8, 2029 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P43/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention relates to the inhibition of VEGF receptor signaling and HGF receptor signaling. The invention provides compounds of general formula (A)wherein A1 is sulfur, A3 is CH, A2 is CH, D is heterocycle, Z is oxygen, SO0-2 or NR, Ar is phenyl and G is not a ring, and methods for inhibiting VEGF receptor signaling and HGF receptor signaling. The invention also provides compositions and methods for treating cell proliferative diseases and conditions.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.